One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
Jurij Hanzel, MD, Jeroen M Jansen, MD, Rinze W F ter Steege, MD, PhD, Krisztina B Gecse, MD, PhD, Geert R D’Haens, MD, PhD
doi : 10.1093/ibd/izab099
Volume 28, Issue 4, April 2022
Intracolonic Neuropeptide Y Y1 Receptor Inhibition Attenuates Intestinal Inflammation in Murine Colitis and Cytokine Release in IBD Biopsies
Bindu Chandrasekharan, PhD, Darra Boyer, BS, Joshua A Owens, PhD, Alexandra A Wolfarth, PhD, Bejan J Saeedi, PhD, Tanvi Dhere, MD, Heba Iskandar, MD, Andrew S Neish, MD
doi : 10.1093/ibd/izab243
Increasing Prevalence and Stable Incidence Rates of Inflammatory Bowel Disease Among First Nations: Population-Based Evidence From a Western Canadian Province
Juan Nicolás Peña-Sánchez, MD, MPH, PhD, Jessica Amankwah Osei, MHEM, MSc, Jose Diego Marques Santos, MSc, Derek Jennings, MEd, PhD, Mustafa Andkhoie, MPH, PhD(c), Colten Brass, Germain Bukassa-Kazadi, MD, MSc, Xinya Lu, MPH, PhD, Michelle Johnson-Jennings, MEd, PhD, Linda Porter, Rob Porter, Carol-Lynne Quintin, Rhonda Sanderson, Ulrich Teucher, PhD, Sharyle Fowler, MD, FRCPC
doi : 10.1093/ibd/izab096
Granulomas in Diagnostic Biopsies Associated With High Risk of Crohn’s Complications—But May Be Preventable
Lindsey S Lawrence, MD, Amer Heider, MD, Andrew A M Singer, MD, Haley C Neef, MD, Jeremy Adler, MD, MSc
doi : 10.1093/ibd/izab109
Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money
Grant A Morris, MD, Megan McNicol, RPh, Brendan Boyle, MD, Amy Donegan, CPNP-PC, Jennifer Dotson, MD, Hilary K Michel, MD, Ross M Maltz, MD
doi : 10.1093/ibd/izab110
Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis
Niels Vande Casteele, PharmD, PhD, Jonathan A Leighton, MD, Shabana F Pasha, MD, Frank Cusimano, DO, Aart Mookhoek, MD, PhD, Catherine E Hagen, MD, Christophe Rosty, MD, PhD, Reetesh K Pai, MD, Rish K Pai, MD, PhD
doi : 10.1093/ibd/izab122
Is Intestinal Diversion an Effective Treatment for Distal Crohn’s Disease?
Amy L Lightner, MD, Hassan Buhulaigah, MD, Karen Zaghiyan, MD, Stefan D Holubar, MD, MS, Scott R Steele, MD, MBA, Xue Jia, MD, John McMichael, Prashansha Vaidya, MD, Phillip R Fleshner, MD
doi : 10.1093/ibd/izab126
Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia
Seth R Shaffer, MD, MS, Amarachi I Erondu, MS, Cindy Traboulsi, MD, Victoria Rai, Noa Krugliak Cleveland, MD, Amanda Israel, MD, Britt Christensen, MD, David T Rubin, MD
doi : 10.1093/ibd/izab130
Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease
Sebastian Bruno Ulrich Jordi, BMed, Brian Matthew Lang, PhD, Bianca Auschra, MSc, Roland von Känel, MD, Luc Biedermann, MD, Thomas Greuter, MD, Philipp Schreiner, MD, Gerhard Rogler, MD, PhD, Niklas Krupka, MD, Michael Christian Sulz, MD, Benjamin Misselwitz, MD, Stefan Begré, MD, Swiss IBD Cohort Study Group
doi : 10.1093/ibd/izab136
STING-mediated Syk Signaling Attenuates Tumorigenesis of Colitis‑associated Colorectal Cancer Through Enhancing Intestinal Epithelium Pyroptosis
Wenbin Gong, PhD, Peizhao Liu, MM, Fan Zhao, PhD, Juanhan Liu, MM, Zhiwu Hong, MD, Huajian Ren, MD, Guosheng Gu, PhD, Gefei Wang, PhD, Xiuwen Wu, MD, Tao Zheng, MD, Yun Zhao, PhD, Jianan Ren, MD, PhD, FACS
doi : 10.1093/ibd/izab217
Neutrophil Extracellular Trap Density Increases With Increasing Histopathological Severity of Crohn’s Disease
Angie L Schroder, BMedSci Hons, Belal Chami, PhD, Yuyang Liu, BMedSci Hons, Chloe M Doyle, BMedSci Hons, Mary El Kazzi, BMedSci Hons, Golo Ahlenstiel, MBBS, Gulfam Ahmad, PhD, Nimalan Pathma-Nathan, MBBS, Geoff Collins, MBBS, James Toh, MBBS, Andrew Harman, PhD, Scott Byrne, PhD, Grahame Ctercteko, MBBS, Paul K Witting, PhD
doi : 10.1093/ibd/izab239
Regional Gray Matter Volume Changes in Brains of Patients With Ulcerative Colitis
Shuming Zhang, BE, Fenrong Chen, MD, Jiayu Wu, ME, Chengxiang Liu, BE, Guang Yang, BE, Ruiqing Piao, BE, Bowen Geng, BE, Ke Xu, BE, Peng Liu, PhD
doi : 10.1093/ibd/izab252
The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis
Jeffrey McCurdy, MD, PhD, FRCPC, Kevin Chin Koon Siw, MD, Rana Kandel, BSc, Sarah Larrigan, BSc, Greg Rosenfeld, MD, Sylvain Boet, MD, PhD
doi : 10.1093/ibd/izab098
Disease Activity Indices for Pouchitis: A Systematic Review
Rocio Sedano, MD, Tran M Nguyen, MSc, Ahmed Almradi, MD, Florian Rieder, MD, Claire E Parker, MA, MLIS, Lisa M Shackelton, PhD, Geert D’Haens, MD, PhD, William J Sandborn, MD, Brian G Feagan, MD, Christopher Ma, MD, Vipul Jairath, MD, PhD
doi : 10.1093/ibd/izab124
Excessive Apoptosis in Ulcerative Colitis: Crosstalk Between Apoptosis, ROS, ER Stress, and Intestinal Homeostasis
Yue Wan, MBBS, Lei Yang, MBBS, Shu Jiang, PhD, Dawei Qian, MBBS, Jinao Duan, PhD
doi : 10.1093/ibd/izab277
Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations
Ryan C Ungaro, MD, MS, Jean-Frederic Colombel, MD, Marla C Dubinsky, MD, Anjali Jain, PhD, Thierry Dervieux,, PharmD, PhD
doi : 10.1093/ibd/izab232
Anti-TNFα Induction Therapy for Patients With Active Inflammatory Bowel Disease During Pregnancy: A Case Series
Michael B MacIsaac, MD, Mette Julsgaard, PhD, Emma Flanagan, PhD, Stephanie Rowe, MD, Alyson L Ross, BN, Richard B Gearry, PhD, Peter R Gibson, MD, Sally J Bell, MD
doi : 10.1093/ibd/izab227
Response to: COVID-19 Vaccination, Willingness, Hesitancy, and Inflammatory Bowel Diseases
Rujittika Mungmunpuntipantip, PhD, Viroj Wiwanitkit, MD
doi : 10.1093/ibd/izab279
Combination Tofacitinib and Calcineurin Inhibitor in the Management of Treatment-Refractory Ulcerative Colitis May Be Effective, But Is It Necessary?
Adam R Peterson, MBBS(Hons), Patrick Hilley, MPharm, Peter De Cruz, PhD
doi : 10.1093/ibd/izab356
Multifaceted Secukinumab-induced Colitis
Alexandros G Sykaras, MD, Evangelia Margellou, MD, Natalia G Vallianou, PhD, Fotis Panagopoulos, MSc, Eleni Geladari, MSc, Dimitris Kounatidis, MSc, Ioannis Alevizakis, MD, Christina Magkou, PhD
doi : 10.1093/ibd/izab267
A Case of Epinephrin-associated Refractory Hypotension Secondary to Lactic Acidosis
Michael Joseph, MD, MPH, Justin Kochanski, MD, Alka Goyal, MD
doi : 10.1093/ibd/izab268
A Rare Case of Hearing Loss in a Patient With Ulcerative Colitis
Chhagan Lal Birda, MD, DM, Ashish Agarwal, MD, DM, Amit Goyal, MS
doi : 10.1093/ibd/izab272
Pseudomembranous Colitis Caused by Haemophilus Parainfluenzae
Qinqin Liu, PhD, Zhiping Jiang, MD, Qingliang Teng, MD, Meijie Jiang, BD
doi : 10.1093/ibd/izab293
Letter of Reply to “Response to: COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients’ Association�
Andrea Costantino, MD, Daniele Noviello, MD, Claudio Costantino, MD, PhD, Maurizio Vecchi, MD, Flavio Caprioli, MD, PhD
doi : 10.1093/ibd/izab281
